Search results for ''
MIMESIS Newsletter #4: A novel systems biology approach to develop preclinical assets
MIMESIS NEWSLETTER #4, December 2018
After two years, ENYO Pharma’s EU funded MIMESIS project was a real success and has delivered several promising new drug development starting points most significantly for RSV and ICD.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”.
J.P. Morgan 37th Annual Healthcare Conference
7 – 10 January, 2019
San Francisco, USA
“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.” (jpmorgan.com)
BioFIT 2018
4 – 5 December, 2018
Lille, France
ENYO Pharma’s CEO Jacky Vonderscher has been invited to speak in the conference programme of BioFIT 2018 in Lille, France, on December 4th and 5th. He had the opportunity to share his experience and knowledge during the following session – agnostic or pure players in the biotech sector: who is becoming prominent in the early-stage financing rounds? He was also able to give ENYO’s experience feedback following the first fundraising in 2016.
Immunotherapies for Infectious Diseases Congress
10 – 11 December, 2018
Lyon, France
ENYO Pharma’s CSO Eric Meldrum is participating today at the I4ID Congress (Immunotherapies for Infectious Diseases Congress) in Lyon, France. I4ID Congress is dedicated to Host-Directed Therapies to fight infectious diseases. During this event, Eric will present new data from ENYO Pharma preclinical programmes to exemplify the power of ENYO Pharma’s drug discovery approach.
“The 2nd edition I4ID2018, follows the success of the first edition,
Participation in La Matinale Santé organized by Bpifrance
ENYO Pharma’s VP Corporate Development & Strategy Nicolas Guyon-Gellin is participating today in “La Matinale Santé” organized by Bpifrance in Paris, France. Bpifrance finances businesses – at every stage of their development – through loans, guarantees and equity investments, but also offers extra financial services. During this event, Nicolas will talk about Bpifrance’s financing and investments actions in the health sector and the role of the Large Venture Fund. This will be a great opportunity to discuss how Bpifrance is currently supporting ENYO Pharma to pursue its growth and development.
Latest Press Release 